Mireille Centlivre

Inserm U955, Université Paris Est
Creteil, 94000, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

Journal: Scientific reports
Published: January 06, 2026

Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.

Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.

Journal: EBioMedicine
Published: September 10, 2025

Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.

Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.

Journal: EBioMedicine
Published: August 02, 2025

Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination.

Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination.

Journal: NPJ vaccines
Published: December 25, 2024

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Journal: EClinicalMedicine
Published: July 08, 2024

A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease.

A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease.

Journal: Cell reports. Medicine
Published: October 06, 2023

Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8+ T cells.

Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8+ T cells.

Journal: EBioMedicine
Published: September 10, 2023

Refining the DC-targeting vaccination for preventing emerging infectious diseases.

Refining the DC-targeting vaccination for preventing emerging infectious diseases.

Journal: Frontiers in immunology
Published: May 21, 2022

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine.

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine.

Journal: EBioMedicine
Published: February 22, 2022

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.

Journal: eLife
Published: November 09, 2021

Single-cell analysis reveals divergent responses of human dendritic cells to the MVA vaccine.

Single-cell analysis reveals divergent responses of human dendritic cells to the MVA vaccine.

Journal: Science signaling
Published: August 25, 2021

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.

Journal: Nature communications
Published: February 18, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026